USA flag logo/image

An Official Website of the United States Government

Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral…

Award Information

Agency:
Department of Agriculture
Branch:
N/A
Award ID:
77596
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
2006-00528
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MOLECULAR TARGETING TECHNOLOGIES, INC.
833 LINCOLN AVE, UNIT 9 WEST CHESTER, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife
Agency: USDA
Contract: 2007-33610-18486
Award Amount: $346,000.00
 

Abstract:

Oral immunization of wildlife and stray dogs with live vaccines is the only effective method to control rabies in carnivore species worldwide. Because adenoviruses replicate on mucosal surfaces, they represent excellent vectors that can be administered both orally and intranasally. The nearly ideal vaccine vector for immunization of carnivores against rabies would be the canine adenovirus type 2 (CAV 2) virus. The CAV 2 vaccine is a very effective livemodified vaccine which has an excellent safety record and which is being used worldwide for the routine vaccination of dogs against both CAV 1 and CAV 2. Although this vaccine is usually administered subcutaneously, it is also effective when administered orally and may allow for limited animal to animal transmission. Previous phase I efforts demonstrated the initial proof of concept through successful construction and selection of CAV 2-RVG viruses followed by evaluation of safety and protective activity in laboratory animals. In this Phase II project we propose to continue evaluation of the vaccine candidate through optimization of virus growth and production of a research viral seed (RVS) stock, genetic and thermal stability studies, in vitro and in vivo safety studies, and safety and efficacy studies in target animals. It is likely that CAV2-RVG will be immunogenic by the oral route in target animals resulting protective immunity against rabies. A key concern to be addressed in this project is the safety of the recombinant virus in target and non-target animals.

Principal Investigator:

Jeffrey A. Mattis
Sr. Vice President, Scientific Affairs
6107387938
jmattis@mtarget.com

Business Contact:

Koon Pak
President and CEO
6107387938
cpak@mtarget.com
Small Business Information at Submission:

Molecular Targeting Technologies, Inc.
882 S. Matlack Street Suite 105 West Chester, PA 19382

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No